Skip to content
Peptilyze
CompoundsShopsCompareMarketLab testsGuidesMethod

Peptides · Reference article

Pinealon Research Overview: Every Study, Mechanism and Gap

Pinealon is a Glu-Asp-Arg tripeptide. We list every cell, animal and human study we could open, who ran it, what is proposed, and what is unreplicated.

Published · Updated · Rests on: 22 PubMed records and 8 further papers opened, 5 small Russian human reports, 1 independent mouse preprint, FDA compounding pages, openFDA, RLS entry, ClinicalTrials.gov (no studies)

This is a reference article, not a price comparison. Peptilyze compares prices of research peptides; it sells nothing and gives no medical advice. Every claim is numbered and listed under Sources.

Pinealon is a three-amino-acid peptide (Glu-Asp-Arg, “EDR”) studied mainly by Vladimir Khavinson’s group in St. Petersburg. Almost everything published about it comes from that group or its collaborators. We found no placebo-controlled human trial and no registered trial [1][2].

Key points

  • About 20 relevant papers exist: cell and rat work from 2008 to 2015, five small Russian human reports from 2012 to 2016, and Alzheimer’s-model and computer work to 2024 [1][3][17].
  • The proposed mechanism, nuclear entry and DNA binding that changes gene expression, rests on one group’s experiments, one physics study and docking. No receptor is identified [3][7][16].
  • The only study outside the Khavinson network is a 2026 mouse preprint (5 per group) with a non-significant trend [20].
  • No regulator we checked approves pinealon as a medicine; Russia lists it as a supplement [27][28][30].
  • Human safety data are essentially absent. For the viral sleep claim, see our claim check.

What pinealon is and where it comes from

Pinealon is the synthetic tripeptide glutamic acid-aspartic acid-arginine. The group’s 2020 review says it was isolated from Cortexin, a polypeptide neuroprotective drug, and notes that oral administration is described as effective but gives no pharmacokinetic data [3]. It sits in the “bioregulator” family of ultrashort peptides, with epitalon (Ala-Glu-Asp-Gly), vesugen (Lys-Glu-Asp) and vilon. The wider family is covered in our Khavinson bioregulator evidence review. Prices are compared on our pinealon page.

What the authors propose, and how it was tested

Antioxidant and anti-necrotic action. A 2011 paper (rat cerebellar granule cells, neutrophils, PC12 cells) found dose-dependent restriction of reactive oxygen species and less necrotic death [4]. A 2008 in-vitro paper from the same lab found no direct antioxidant activity [6], and a 2008 hypoxia paper proposed stimulation of the cell’s own antioxidant enzymes [5]. In people, the 2015 report found pro-oxidant activity [23]. These accounts do not agree.

Signalling. The 2011 paper saw a delayed time course of ERK1/2 activation [4]. Caspase-3 findings in old rats vary between papers: one reports a moderate rise with pinealon after carotid occlusion, the group’s 2020 review reports reduced expression and prevented activation in other hypoxia models [9][3].

Direct interaction with DNA. The 2011 authors inferred it indirectly: ROS protection saturated at low concentrations while cell-cycle effects continued, so the peptide “is able to interact directly with the cell genome” [4]. Later work:

  • A 2011 HeLa-cell study (first author in Moscow, Khavinson co-author) found labelled pinealon in the nucleus and sequence-dependent quenching with synthetic oligonucleotides [7].
  • A 2019 solution study from St. Petersburg State University physicists (no Khavinson among the authors) used NMR and molecular dynamics and reported partial entry into the DNA major groove near guanine atoms [16].
  • Group docking studies predict EDR sites in promoters of genes including TPH1, CASP3, SOD2 and PPARA [13][17]. These are computer predictions; we found no experiment confirming promoter binding in living cells.
  • Cultured rat cortex cells showed more serotonin expression [13]. The 2015 human study found no change in chromatin condensation [23].

Receptors and uptake. The 2020 review names no EDR receptor [3]. A 2023 docking paper proposes uptake via the transporters LAT1, LAT2 and PEPT1, again in silico [18].

Apart from the 2019 physics paper, every mechanistic claim above comes from one group.

Every study we could open

“Group” is the authors’ network. Sizes are those the abstracts or full text give; “not stated” means we could not see it.

Year System Size Finding Group
2008 Rats, hypoxia Not stated Strongest of four peptides against hypoxia [5] Khavinson network
2008 Cells, lipoproteins, red cells Not stated Fewer dead neurons; no direct antioxidant activity [6] Khavinson
2011 Rat cerebellar cells, neutrophils, PC12 Not stated Less ROS and necrosis; delayed ERK1/2 [4] Khavinson
2011 HeLa cells, oligonucleotides Not stated Reaches nucleus; binds sequences [7] Moscow plus Khavinson
2011 Rat pineal organ culture Not stated No effect on apoptosis marker AIF [8] Khavinson
2011 Old rats, carotid occlusion Not stated Higher survival; caspase-3 moderately up [9] Mendzheritskii
2012 Rat offspring, methionine diet Not stated Better learning; less cell death [10] Khavinson
2012 Rat skin explants Not stated More proliferation in young, not old, tissue [11] St. Petersburg
2013 Rats, Morris maze Not stated Better learning than Cortexin, young and old [12] Mendzheritski
2014 Rat cortex cell culture Not stated More serotonin expression; docking [13] Khavinson
2014-15 Old rats, hypoxia, hypothermia Not stated Cytokine, monoamine changes [14][15] Mendzheritskii
2019 DNA in solution n/a Partial major-groove binding [16] SPbU physics
2021 5xFAD Alzheimer’s mice 10 per group, 2 months Spine density up about 11%; LTP trend not significant [17] Khavinson
2024 Human fibroblast-derived neurons Not stated Less DNA damage; more dendrites; no effect on p16 [19] Khavinson
2026 C57BL/6J mice, preprint 5 males per group, 8 weeks Non-significant working-memory trend [20] Spain/Switzerland
2012 Locomotive crews Not stated Better “biological age” scores after two weeks [21] Russian geriatrics
2012 150 drivers, 150 metalworkers 300 Mood indices improved; unclear arm [22] Bashkireva
2015 Adults 41-83 with brain syndrome 32 Pro-oxidant; fewer CD34+ cells [23] Meshchaninov
2015 Workers with occupational hazards Not stated Work-ability index [24] Bashkireva
2016 Mixed ages vs baths, oxygen, massage 110 Best result with pinealon plus vesugen [25] Myakotnykh

The 2020 review credits a 2013 article by Umnov, Linkova and Khavinson with a 72-patient brain-injury study reporting better memory and less headache [3][26]. That article’s PubMed record is a review, and we could not open the data.

None of the five human reports is described as blinded or placebo-controlled; endpoints are “biological age” indices and questionnaires, and several combine pinealon with vesugen. The 2021 mouse paper states no external funding or conflict of interest; a 2025 correction exists that we did not review [17].

Has anyone outside the network replicated it?

Not in a way we can confirm. Searches of PubMed and Europe PMC (2026-11-08) turned up no independent replication of the cell, learning or Alzheimer’s findings [1][35]. The 2019 DNA study is independent of the Khavinson authors but is physical chemistry and says nothing about biology [16].

The 2026 preprint (Switzerland and Spain) tested pinealon among five candidates: 5 male mice per group, aged 8 months at the start, 8 weeks. It reported a non-significant trend in alternation and “without obvious adverse effects” [20]. It is not peer reviewed. Two authors state they own shares in the contract lab and in Pump.Science, which with token communities funded it; one listed token has the ticker $PNL, and we did not verify what it represents [20]. We did not search Russian-language databases such as eLibrary.

How sellers describe it, and what is shown

Seller or promoter wording What the sources show
Crosses the blood-brain barrier, enters nuclei, raises melatonin, improves REM sleep [32] No pharmacokinetic data in the 2020 review [3]; nuclear entry shown in HeLa cells [7]; no sleep or melatonin outcome in the human reports [21][22][23][24][25]
“Small human trial” in older adults [32] Small, unblinded Russian reports without placebo arms [23][25]
“pinealon before bed + 6h sleep = waking up like a kid on christmas morning” [33] No sleep study found
“Research use only”, 99% purity, “tested for identity” [36] A label, not an approval; we cannot verify the claim

A 2026 health-service guide says there are no completed randomized human trials and calls the mechanism “contested outside that laboratory network” [31]. We did not verify its other statements.

Regulatory status

  • United States (checked 2026-11-08). No match for pinealon in the openFDA Drugs@FDA and label endpoints [29]. The FDA’s page on compounding substances (current as of 2026-04-22) does not name pinealon, though it lists epitalon, BPC-157 and others as nominated but withdrawn [27]. The 503A bulks page (current 2026-05-14) does not name it either [28]. No FDA approval found.
  • Russia (RLS entry updated 2022-08-08). Listed as a dietary supplement, “additional source of peptides”, with no registration number or manufacturer shown [30]. The Russian human reports call these peptides “cytogens” [22].
  • EU, UK, Germany: not checked against EMA, MHRA or BfArM registers. Web searches found no approval, but those were vendor and blog pages.
  • ClinicalTrials.gov: no registered pinealon study [2].
  • “Research use only” means sold as a laboratory reagent, outside medicine and food rules. It is not an approval and no regulator has checked purity or safety.

Risks and unknowns

The 2015 report on 32 adults recorded pro-oxidant activity and fewer CD34+ blood cells, which its authors read as significant inhibition of haematopoiesis, while calling the peptides “safe on nuclear genetic level” [23]. The 2016 report called massage and oligopeptide preparations the safest of the methods compared, without adverse-event counts in the abstract [25]. The 2026 mouse preprint saw no obvious harm in 5 animals over 8 weeks [20].

No data found on: interactions, pregnancy, children, long-term use, dose-response in people, immunogenicity, or product purity. The 2020 review’s safety remarks concern bioregulators in general, not EDR [3]. Open scientific questions: whether the nuclear effect occurs at body concentrations; whether any DNA site is bound in cells; why different papers disagree on antioxidant and caspase-3 effects; and whether any benefit survives a blinded, placebo-controlled design.

Epitalon, vesugen and vilon share the pattern: Khavinson-network cell, rodent and small Russian human work. Epitalon has at least one co-authored paper with a university in Chieti, Italy, with Khavinson as first author [34]. Epitalon, unlike pinealon, appears on the FDA withdrawn-nominations list [27]. See our pages on epitalon, vilon and vesugen.

Frequently asked questions

Is pinealon approved anywhere? Not as a medicine in the sources we checked. Russia lists it as a dietary supplement. We did not check EMA, MHRA or BfArM registers [27][30].

Has pinealon been tested in humans? In five small Russian reports from 2012 to 2016, none described as placebo-controlled, plus a 72-patient study we could not open [3][21][25].

Does anyone outside the Khavinson group support the findings? One 2026 mouse preprint found only a non-significant trend. Independent confirmation of the cell and rat findings is lacking [20].

How does it supposedly work? Authors propose it enters the nucleus and binds DNA, altering gene expression. Evidence is in vitro and computational, and no receptor is known [3][7][16].

Sources

  1. NCBI PubMed, search “pinealon”, 22 records (run 2026-11-08). https://pubmed.ncbi.nlm.nih.gov/?term=pinealon
  2. ClinicalTrials.gov API v2, query “pinealon”, empty result (run 2026-11-08). https://clinicaltrials.gov/api/v2/studies?query.term=pinealon
  3. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S, “EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease,” Molecules (2020-12-31). https://pmc.ncbi.nlm.nih.gov/articles/PMC7795577/
  4. Khavinson V, et al., “Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes,” Rejuvenation Research (2011). https://pubmed.ncbi.nlm.nih.gov/21978084/
  5. Kozina LS, “Investigation of antihypoxic properties of short peptides,” Advances in Gerontology (2008). https://pubmed.ncbi.nlm.nih.gov/18546825/
  6. Kozina LS, et al., “Biological activity of regulatory peptides in model experiments in vitro,” Advances in Gerontology (2008). https://pubmed.ncbi.nlm.nih.gov/18546826/
  7. Fedoreyeva LI, et al., “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells…,” Biochemistry (Moscow) (2011). https://pubmed.ncbi.nlm.nih.gov/22117547/
  8. Khavinson VKh, et al., “Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture,” Bull Exp Biol Med (2011). https://pubmed.ncbi.nlm.nih.gov/22803060/
  9. Mendzheritskii AM, et al., “Effects of introduction of short peptides before carotid artery occlusion…,” Advances in Gerontology (2011). https://pubmed.ncbi.nlm.nih.gov/21809624/
  10. Arutjunyan A, et al., “Pinealon protects the rat offspring from prenatal hyperhomocysteinemia,” Int J Clin Exp Med (2012). https://pubmed.ncbi.nlm.nih.gov/22567179/
  11. Voicekhovskaya MA, et al., “Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats,” Bull Exp Biol Med (2012). https://pubmed.ncbi.nlm.nih.gov/22803085/
  12. Mendzheritski AM, et al., “Effect of peptide geroprotectors on the navigation system learning and caspase-3…,” Advances in Gerontology (2013). https://pubmed.ncbi.nlm.nih.gov/28976148/
  13. Khavinson VKh, et al., “Short peptides stimulate serotonin expression in cells of brain cortex,” Bull Exp Biol Med (2014). https://pubmed.ncbi.nlm.nih.gov/24909721/
  14. Mendzheritskii AM, et al., “Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats…,” Advances in Gerontology (2014). https://pubmed.ncbi.nlm.nih.gov/25051764/
  15. Mendzheritsky AM, et al., “Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats…,” Advances in Gerontology (2015). https://pubmed.ncbi.nlm.nih.gov/28509493/
  16. Silanteva IA, et al., “Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction,” J Phys Chem B (2019). https://pubmed.ncbi.nlm.nih.gov/30762356/
  17. Khavinson V, et al., “Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease,” Pharmaceuticals (2021; corrected 2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC8227791/
  18. Khavinson VK, et al., “Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters,” Biomolecules (2023). https://pubmed.ncbi.nlm.nih.gov/36979488/
  19. Kraskovskaya N, et al., “Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes,” Int J Mol Sci (2024). https://pubmed.ncbi.nlm.nih.gov/39518916/
  20. Marín-Jerez E, et al., “Short-Term Performance Assay Identifies Functional Benefits and Early Toxicity of Longevity Interventions in Mice,” bioRxiv preprint (2026-02-26). https://doi.org/10.64898/2026.02.25.707674
  21. Nazimko VA, et al., “Analysis of some parameters of biological age… of workers of locomotive brigades,” Advances in Gerontology (2012). https://pubmed.ncbi.nlm.nih.gov/22708445/
  22. Bashkireva AS, Artamonova VG, “The peptide correction of neurotic disorders among professional truck-drivers,” Advances in Gerontology (2012). https://pubmed.ncbi.nlm.nih.gov/23734521/
  23. Meshchaninov VN, et al., “Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome in remission,” Advances in Gerontology (2015). https://pubmed.ncbi.nlm.nih.gov/26390612/
  24. Bashkireva AS, Kachan EY, “Assessment of work ability index in evaluation of small peptides geroprotective effect,” Advances in Gerontology (2015). https://pubmed.ncbi.nlm.nih.gov/28509489/
  25. Myakotnykh VS, et al., “Comparative analysis of different methods of geroprotective,” Advances in Gerontology (2016). https://pubmed.ncbi.nlm.nih.gov/28539017/
  26. Umnov RS, Linkova NS, Khavinson VKh, “Neuroprotective effects of peptides bioregulators in people of various age,” Advances in Gerontology (2013), abstract only. https://pubmed.ncbi.nlm.nih.gov/24738258/
  27. FDA, “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (current as of 2026-04-22). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  28. FDA, “Bulk Drug Substances Used in Compounding Under Section 503A of the FDCA” (current as of 2026-05-14). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  29. openFDA, Drugs@FDA and drug label endpoints, search “pinealon”, no matches (run 2026-11-08). https://api.fda.gov/drug/drugsfda.json
  30. RLS (rlsnet.ru), “Пинеалон” dietary supplement entry (updated 2022-08-08). https://www.rlsnet.ru/baa/pinealon-30390
  31. Superpower, “Pinealon: A Pineal-Derived Tripeptide for Cognitive and Neuroprotective Research” (published 2026-04-18, updated 2026-09-30); secondary source. https://superpower.com/guides/pinealon
  32. Hunter’s Health Hacks newsletter, “pinealon for longevity” (undated, 2026 footer); promotes a product with a discount code. https://huntershealthhacks.beehiiv.com/p/pinealon-for-longevity
  33. @limitlesstack, post of 2026-10-27, text confirmed through the fxtwitter mirror because X blocks automated access. https://x.com/limitlesstack/status/2115145487695364467
  34. Khavinson V, et al., “AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis,” Molecules (2020). https://pubmed.ncbi.nlm.nih.gov/32019204/
  35. Europe PMC, search “pinealon” (run 2026-11-08). https://europepmc.org/search?query=pinealon
  36. UK research-chemical vendor product page, read 2026-11-08 (metadata text only); URL withheld under Peptilyze’s no-product-links rule.

This article is information, not medical advice.

More in Peptides